The Progeria Research Foundation is the only organization in the world dedicated to discovering treatments and the cure for Progeria and its aging-related disorders. Progeria is a rare, fatal, “premature aging” disease that affects children, who die of cardiovascular disease (heart failure or stroke) at an average age of 14 years — the same diseases that affect millions of normal aging adults (atherosclerosis and stroke). Investigation of the disease mechanisms causing Progeria will help not only children with Progeria, but also has implications for heart attacks, strokes and other aging-related conditions.
PRF’s research focus is highly translational. Topics must fall within any of the following research priorities: projects that are likely to lead to clinical treatment trials within five years, including the discovery and/or testing of candidate treatment compounds in cell-based or animal models of HGPS; the development of gene- and cell-based therapies to treat Progeria; and/or assessments of the natural history of disease that may be important to developing outcome measures in treatment trials (preclinical or clinical).
Awards are typically for one to two years at a maximum of $75,000 per year.
Principal investigators must hold a faculty appointment or equivalent. Awards will be granted only to applicants affiliated with institutions with 501(c)(3) tax-exempt status, or the equivalent for foreign institutions.
A two-page Letter of Intent is due by January 2, 2020 at 5:00 p.m. EST.
For the complete RFP and additional information, see the Progeria Research Foundation website.